News / Testing plane sewage at border can help detect disease

Testing plane sewage at border can help detect disease

airport

Testing wastewater from international aircraft arriving in Aotearoa can identify new and potentially dangerous infectious diseases not already present in the country, according to research led by the Institute of Environmental Science and Research (ESR) and funded by Te Niwha.

Researchers collected sewage waste from more than 80 international aircraft on arrival in New Zealand in late 2024. The wastewater was then tested for the presence of potential disease-causing bacteria and viruses.

Using new metagenomics technology, researchers were not only able to detect the virus that causes COVID-19 in the wastewater, but specific variants not known to be present in Aotearoa at the time, but which subsequently showed up in council wastewater surveillance.

Researchers also identified other viruses, funguses and bacteria of potential health concern, including Adenovirus, which can cause severe respiratory problems, Shigella, which causes diarrhea and Candida tropicalis which can be dangerous to immunocompromised individuals.

Te Niwha is the national infectious diseases research platform and funds scientists and communities to do work that ensures Aotearoa is best prepared for the next pandemic and existing disease threats.

The wastewater project was co-led by ESR senior scientists Drs Brent Gilpin and Jo Chapman.

Dr Gilpin says the project aimed to determine whether testing international aircraft sewage could accurately identify infectious diseases present in different parts of the world before they became established in Aotearoa.

“We found the technology worked and it is an efficient way to boost existing surveillance and give authorities a heads-up on diseases at the border before they gain a foothold in the community or health care facilities.

“Our research proved that during a future pandemic or major infectious disease outbreak, screening aircraft wastewater is a feasible, cost-effective and non-invasive method for early detection at the border of infectious diseases, and even specific subtypes/variants. The technology can also help understand diseases circulating around the world and whether diseases are increasing, remaining stable, or declining. For diseases we don’t see often in New Zealand, detection of new pathogens in wastewater could be used to prompt clinicians and testing laboratories to consider requesting tests for those diseases, particularly if there is a an increase in undiagnosed illness.”

Dr Gilpin says the research team trialled new metagenomic sequencing methods that identify all microbes in a sample, instead of those specifically tested for.

“Using these methods, we were able to identify thousands of different microorganisms present in the aircraft wastewater samples. While many of the bacteria detected were associated with normal gut microflora, organisms of potential health concern were detected.”

Dr Gilpin says the technology identifies people on the aircraft with particular organisms in their digestive system but does not indicate if they are infectious or infection occurred on the flight as people continue to shed microbes in their stool for weeks after recovering from an infection.

Dr Jo Chapman says there is huge international interest in the potential of testing aircraft wastewater to monitor infectious disease spread, with the establishment last year of GLOWACON, the Global Consortium for Wastewater and Environmental Surveillance for Public Health. Through this Te Niwha project, New Zealand is actively helping shape the use of this technology, she says.

Dr Chapman says a second phase of the Te Niwha-funded study will focus on the best way to test sewage from individual buildings, such as hospitals, to determine the presence of certain infectious disease – and when they are no longer present.

“The practical focus of this research mahi is developing an appropriate and effective means for implementation of wastewater analysis in smaller-scale settings. This sampling closer to the source and of smaller populations could allow new opportunities for early detection of infectious diseases, confirmation of the elimination of diseases, and better public health understanding of underrepresented populations,’ Dr Chapman says.

An important aspect of the research is engaging with tāngata whenua, Pacific Peoples, local communities, airlines, government and public health organisations to understand whether small-scale wastewater sampling of aircraft or buildings or smaller more isolated communities is of value to them and to understand ethical implications, she says.

Te Niwha Mana Whakahaere I Director Te Pora Thompson says a lot was learnt from the COVID-19 experience, including the importance of robust surveillance systems and connections with international agencies to ensure Aotearoa New Zealand is prepared for future pandemics or the emergence of new and dangerous infectious diseases.

“Te Niwha’s mahi ranges from improving surveillance to developing new antiviral drugs. Work involves government agencies, non-government agencies, and communities as well as researchers and science organisations.”

Te Niwha